医学
内科学
荟萃分析
肿瘤科
结直肠癌
辅助化疗
梅德林
循环肿瘤DNA
化疗
癌症
法学
政治学
乳腺癌
作者
Emre Yekedüz,Elif Berna Köksoy,Hakan Akbulut,Yüksel Ürün,Güngör Utkan
出处
期刊:Future Oncology
[Future Medicine]
日期:2020-12-24
卷期号:17 (3): 349-357
被引量:6
标识
DOI:10.2217/fon-2020-0671
摘要
Aim: Using circulating tumor DNA (ctDNA) instead of historical clinicopathological factors to select patients for adjuvant chemotherapy (ACT) may reduce inappropriate therapy. Material & methods: MEDLINE was searched on 31 March 2020. Studies, including data related to the prognostic value of ctDNA in the colon cancer patients after surgery and after ACT, were included. The generic inverse-variance method with a random-effects model was used for meta-analysis. Results: Four studies were included for this meta-analysis. ctDNA-positive colon cancer patients after surgery and ACT had a significantly increased risk of recurrence compared with ctDNA-negative patients. Conclusions: ctDNA is an independent prognostic factor, and this meta-analysis is a significant step for using ctDNA instead of historical prognostic factors in the adjuvant setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI